Anbio Biotechnology (NNNN) Cash & Equivalents (2023 - 2025)

Anbio Biotechnology (NNNN) has reported Cash & Equivalents for 3 consecutive years, with $7.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 33.96% year-over-year to $7.8 million; the TTM figure through Dec 2025 stood at $7.8 million (down 33.96% YoY), while the FY2025 annual figure was $7.8 million, down 33.96% from the prior year.
• Cash & Equivalents fell to $7.8 million in Q4 2025 per NNNN's latest filing, from $5348.5 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $5348.5 billion in Q2 2025 and bottomed at $7.8 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $1337.1 billion across 3 years, with a median of $10.7 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents gained 21.4% — and 2025, when it slumped 33.96%.
• Anbio Biotechnology's Cash & Equivalents stood at $9.7 million in 2023, then gained by 21.4% to $11.8 million in 2024, then plunged by 33.96% to $7.8 million in 2025.
• Business Quant data shows NNNN's Cash & Equivalents at $7.8 million in Q4 2025, $5348.5 billion in Q2 2025, and $11.8 million in Q4 2024.